Stock Analysts

Nokia-Tencent Partnership to Benefit Internet Users in China

Nokia Corporation NOK recently inked an agreement with Tencent to carry out joint research and development work in 5G to benefit the Internet users of China. The strategic framework aims to pool in resources of both the companies for the overall improvement of the industry and is likely to be a win-win deal. […]

Stock Analysts

Chemical Production on the Upswing: 5 Growth Stocks to Buy

Global chemical production continued its uptrend in the second quarter with May seeing a rise in production on broad-based regional gains in output and increased capacity utilization, according to the recent monthly report from the American Chemistry Council (ACC). Growth Accelerates in May The chemical industry trade group said that the Global Chemical Production Regional Index (CPRI) rose 0.9% in May on a monthly comparison basis, an improvement from a 0.4% gain in April. The gains in chemical production in the second quarter also marks a turnaround from a decline in output through the first quarter […]

Stock Analysts

Bristol-Myers’ Sprycel Gets EC Approval for Label Expansion

Bristol-Myers Squibb Company BMY announced that the European Commission (EC) has approved the label expansion of oncology drug Sprycel. Consequently, the drug is now approved for the treatment of children and adolescents aged one year to 18 years with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). It also includes a powder for oral suspension formulation. […]

Momentum Stocks

Bear of the Day: 8×8 Inc. (EGHT)

Headquartered in San Jose, CA, 8×8 ( EGHT ) is company that provides cloud-based phone, meeting, collaboration, and contact center solutions. With its applications, the company hopes to reduce complexity and cost, as well as improve individual and team productivity and performance, and enhance the overall customer experience. […]

Stock Analysts

Biotech Stock Roundup: GILD’s Positive CHMP Nod, Regulatory Updates & More

It’s been a pretty low-key week for the biotech sector, with not too many major updates. Among the key news, Gilead’s GILD CAR-T therapy won CHMP positive opinion, while Keryx Biopharmaceuticals KERX plunged on merger news. Recap of Important Stories : Gilead’s CAR-T Therapy Gets Positive CHMP Opinion : Gilead announced that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion on the company’s Marketing Authorization Application ("MAA") for CAR T therapy, axicabtagene ciloleucel, as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma ("DLBCL") and primary mediastinal large B-cell lymphoma ("PMBCL"), after two or more lines of systemic therapy. […]

Stock Analysts

Why a Hold Strategy Is Apt for ExxonMobil (XOM) Stock Now

We issued an updated research report on Exxon Mobil Corporation XOM on Jul 5, 2018. Being the largest publicly-traded energy firm, the company has a lead position in the energy industry owing to size and diversity of asset base, in terms of business mix and geographical footprint. However, the pipeline bottleneck problem is likely to dampen the company’s domestic production. […]